ISPOR Europe 2025

RWE is driving decisions in regulatory strategy, health economics, early pipeline design and market access. Certara’s expert RWE and modeling team combines >100 collective years of experience with a proven ability to provide timely, strategic value across epidemiology, clinical operations, data science, modeling and biostatistics.

Meet our experts at this year’s ISPOR Europe event Glasgow to learn how Certara’s integrated capabilities support value demonstration throughout drug development.

• RWE studies – data acquisition, design, execution and analysis
• Modeling and simulation – advanced modeling (ITCs, ML-based models and surrogate endpoint analysis) and health economic models (cost effectiveness, budget impact) to support strategic positioning and health technology assessment (HTA) value dossiers

• Publication: Critical roles for Modeling and Simulation and RWE to Inform Challenges in Clinical Trial Diversity Planning
• Case Study: Joint Clinical Assessment (JCA) and Potential Consequences for the Evaluation of Gene Therapies
• Case Study: Using Real World Evidence to Inform Treatment Guidelines
• Announcement: Certara Awarded European Medicines Agency Project to Assess RWD Landscape for CAR-T Cell Therapies
• White Paper: Everything you need to know about ILAP 2.0
• Blog: Using cost-effectiveness models for smarter drug development and healthcare decisions
• Blog: ‘Most Favored Nation’ Policy Could Have Profound Impact on Global Drug Pricing if Fully Implemented